---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-108413"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2025-08-14T23:59:59+00:00"
generated_at: "2026-05-17T13:15:28.141036+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics Q2 net loss $31.2M; pauses IV SMARCA2 degrader, focuses on oral PRT7732

## Summary
- Net loss of $31.2M ($0.41 per share) improved from $34.7M ($0.46) in Q2 2024.
- Cash, equivalents and marketable securities $77.3M; runway into Q2 2026.
- PRT3789 (IV) Phase 1 completed; will only advance with partnership. Oral PRT7732 enrolling 7th cohort (125 mg once daily); initial data by year-end 2025.
- KAT6A degrader development candidate selected; IND on track for H1 2026.
- R&D expense $25.8M (down from $29.5M); G&A $6.4M (down from $7.7M) YoY.

## SEC filing metadata
- accession: 0000950170-25-108413
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2025-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/0000950170-25-108413-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000095017025108413/prld-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-108413
- JSON: https://secwatch.observer/filing/0000950170-25-108413.json
- Plain text: https://secwatch.observer/filing/0000950170-25-108413.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.